SG11202100719YA - Heterobicyclic compounds for inhibiting the activity of shp2 - Google Patents
Heterobicyclic compounds for inhibiting the activity of shp2Info
- Publication number
- SG11202100719YA SG11202100719YA SG11202100719YA SG11202100719YA SG11202100719YA SG 11202100719Y A SG11202100719Y A SG 11202100719YA SG 11202100719Y A SG11202100719Y A SG 11202100719YA SG 11202100719Y A SG11202100719Y A SG 11202100719YA SG 11202100719Y A SG11202100719Y A SG 11202100719YA
- Authority
- SG
- Singapore
- Prior art keywords
- shp2
- inhibiting
- activity
- heterobicyclic compounds
- heterobicyclic
- Prior art date
Links
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018138244 | 2018-07-24 | ||
| PCT/JP2019/028822 WO2020022323A1 (en) | 2018-07-24 | 2019-07-23 | Heterobicyclic compounds for inhibiting the activity of shp2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100719YA true SG11202100719YA (en) | 2021-02-25 |
Family
ID=69180650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100719YA SG11202100719YA (en) | 2018-07-24 | 2019-07-23 | Heterobicyclic compounds for inhibiting the activity of shp2 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220363693A1 (en) |
| EP (1) | EP3827009A4 (en) |
| JP (1) | JP7174143B2 (en) |
| KR (1) | KR102579709B1 (en) |
| CN (1) | CN112513050A (en) |
| AU (1) | AU2019309987B2 (en) |
| BR (1) | BR112021001292A2 (en) |
| CA (1) | CA3107411C (en) |
| EA (1) | EA202190342A1 (en) |
| IL (1) | IL280331B2 (en) |
| MA (1) | MA53395A (en) |
| MX (1) | MX2021000795A (en) |
| PH (1) | PH12021550167A1 (en) |
| SA (1) | SA521421089B1 (en) |
| SG (1) | SG11202100719YA (en) |
| TW (1) | TW202019921A (en) |
| WO (1) | WO2020022323A1 (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| CN109475531B (en) | 2016-05-31 | 2021-08-17 | 得克萨斯州立大学董事会 | Heterocyclic inhibitors of PTPN11 |
| WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW201819386A (en) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | SHP2 phosphatase inhibitors and methods of use thereof |
| WO2018218133A1 (en) | 2017-05-26 | 2018-11-29 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| WO2019067843A1 (en) | 2017-09-29 | 2019-04-04 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| WO2019167000A1 (en) | 2018-03-02 | 2019-09-06 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical compounds |
| US20220315586A1 (en) | 2018-03-21 | 2022-10-06 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| BR112020022224A2 (en) | 2018-05-02 | 2021-06-08 | Navire Pharma, Inc. | ptpn11 substituted heterocyclic inhibitors |
| CN112601750B (en) | 2018-08-10 | 2023-10-31 | 纳维尔制药有限公司 | PTPN11 (SHP 2) inhibitors |
| CA3113233A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| EP4031542A4 (en) | 2019-09-18 | 2023-10-25 | Merck Sharp & Dohme LLC | Small molecule inhibitors of kras g12c mutant |
| CN114450287A (en) | 2019-09-24 | 2022-05-06 | 传达治疗有限公司 | SHP2 phosphatase inhibitors and methods of making and using the same |
| KR20220106980A (en) | 2019-10-28 | 2022-08-01 | 머크 샤프 앤드 돔 코포레이션 | Small molecule inhibitors of KRAS G12C mutants |
| US20230023023A1 (en) | 2019-10-31 | 2023-01-26 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| CN114901662A (en) | 2019-11-08 | 2022-08-12 | 锐新医药公司 | Bicyclic heteroaryl compounds and uses thereof |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| TW202140024A (en) * | 2020-01-24 | 2021-11-01 | 日商大鵬藥品工業股份有限公司 | Enhancement of anti-tumor activity of shp2 inhibitor pyrimidinone in combination with novel cancer medicines in cancers |
| WO2021215545A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
| US20230174518A1 (en) | 2020-04-24 | 2023-06-08 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| WO2021257736A1 (en) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| EP4183395A1 (en) | 2020-07-15 | 2023-05-24 | Taiho Pharmaceutical Co., Ltd. | Pyrimidine compound-containing combination to be used in tumor treatment |
| WO2022043865A1 (en) | 2020-08-24 | 2022-03-03 | Taiho Pharmaceutical Co., Ltd. | Crystalline form of heterobicyclic compound |
| JP2023541236A (en) | 2020-09-03 | 2023-09-29 | レボリューション メディシンズ インコーポレイテッド | Use of SOS1 inhibitors to treat malignant tumors with SHP2 mutations |
| TW202227460A (en) | 2020-09-15 | 2022-07-16 | 美商銳新醫藥公司 | Ras inhibitors |
| EP4039685A1 (en) * | 2021-02-08 | 2022-08-10 | Irbm S.P.A. | Azabicyclic shp2 inhibitors |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| EP4334325A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| AU2022270116A1 (en) | 2021-05-05 | 2023-12-21 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4347041A1 (en) | 2021-05-28 | 2024-04-10 | Taiho Pharmaceutical Co., Ltd. | Small molecule inhibitors of kras mutated proteins |
| WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
| TW202317100A (en) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers |
| WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| CN113717178B (en) * | 2021-09-30 | 2022-07-22 | 上海皓鸿生物医药科技有限公司 | Intermediate of SHP2 inhibitor and preparation method thereof |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| WO2023168036A1 (en) | 2022-03-04 | 2023-09-07 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| CN117088887A (en) * | 2022-05-20 | 2023-11-21 | 安徽中科拓苒药物科学研究有限公司 | SHP2 inhibitors and uses thereof |
| TW202404581A (en) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Mek inhibitors and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN116589410B (en) * | 2023-05-29 | 2024-05-03 | 济南国鼎医药科技有限公司 | Synthesis method of 6-chloro-2-methyl-2H-indazole-5-amine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9023865B2 (en) * | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| JP6361562B2 (en) | 2015-04-17 | 2018-07-25 | 株式会社デンソー | Motor control device and electric power steering device |
| US10975080B2 (en) * | 2015-06-19 | 2021-04-13 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| BR112017027951A2 (en) * | 2015-06-22 | 2018-08-28 | Ono Pharmaceutical Co., Ltd. | brk inhibitory compound |
| WO2017156397A1 (en) * | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
| CN109475531B (en) * | 2016-05-31 | 2021-08-17 | 得克萨斯州立大学董事会 | Heterocyclic inhibitors of PTPN11 |
| WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW201819386A (en) * | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | SHP2 phosphatase inhibitors and methods of use thereof |
| AU2018207464B2 (en) * | 2017-01-10 | 2020-05-14 | Novartis Ag | Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor |
| BR112020009757A2 (en) * | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | polycyclic compounds as allosteric inhibitors of shp2 |
| WO2019165073A1 (en) * | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| WO2019167000A1 (en) * | 2018-03-02 | 2019-09-06 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical compounds |
-
2019
- 2019-07-23 KR KR1020217005654A patent/KR102579709B1/en active IP Right Grant
- 2019-07-23 EA EA202190342A patent/EA202190342A1/en unknown
- 2019-07-23 US US17/262,341 patent/US20220363693A1/en active Pending
- 2019-07-23 CA CA3107411A patent/CA3107411C/en active Active
- 2019-07-23 MA MA053395A patent/MA53395A/en unknown
- 2019-07-23 EP EP19840404.8A patent/EP3827009A4/en active Pending
- 2019-07-23 AU AU2019309987A patent/AU2019309987B2/en active Active
- 2019-07-23 WO PCT/JP2019/028822 patent/WO2020022323A1/en unknown
- 2019-07-23 IL IL280331A patent/IL280331B2/en unknown
- 2019-07-23 TW TW108126068A patent/TW202019921A/en unknown
- 2019-07-23 BR BR112021001292-3A patent/BR112021001292A2/en unknown
- 2019-07-23 CN CN201980048743.7A patent/CN112513050A/en active Pending
- 2019-07-23 MX MX2021000795A patent/MX2021000795A/en unknown
- 2019-07-23 SG SG11202100719YA patent/SG11202100719YA/en unknown
- 2019-07-23 JP JP2021503177A patent/JP7174143B2/en active Active
-
2021
- 2021-01-21 PH PH12021550167A patent/PH12021550167A1/en unknown
- 2021-01-24 SA SA521421089A patent/SA521421089B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3827009A1 (en) | 2021-06-02 |
| JP2021531296A (en) | 2021-11-18 |
| IL280331B1 (en) | 2023-08-01 |
| PH12021550167A1 (en) | 2021-09-13 |
| AU2019309987A1 (en) | 2021-03-11 |
| IL280331A (en) | 2021-03-25 |
| US20220363693A1 (en) | 2022-11-17 |
| SA521421089B1 (en) | 2023-01-22 |
| CA3107411C (en) | 2023-09-26 |
| CA3107411A1 (en) | 2020-01-30 |
| CN112513050A (en) | 2021-03-16 |
| MX2021000795A (en) | 2021-04-12 |
| EP3827009A4 (en) | 2022-04-27 |
| TW202019921A (en) | 2020-06-01 |
| EA202190342A1 (en) | 2021-07-22 |
| MA53395A (en) | 2021-06-02 |
| KR20210040399A (en) | 2021-04-13 |
| BR112021001292A2 (en) | 2021-05-11 |
| WO2020022323A1 (en) | 2020-01-30 |
| KR102579709B1 (en) | 2023-09-15 |
| IL280331B2 (en) | 2023-12-01 |
| JP7174143B2 (en) | 2022-11-17 |
| AU2019309987B2 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280331A (en) | Heterobicyclic compounds for inhibiting the activity of shp2 | |
| IL304526A (en) | Manufacture of compounds and compositions for inhibiting the activity of shp2 | |
| PL3468972T3 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| HRP20181832T1 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 | |
| IL268030A (en) | Bicyclic compounds as allosteric shp2 inhibitors | |
| IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL273428B1 (en) | Heterocyclic compounds as pad inhibitors | |
| EP3929197C0 (en) | Intermediates for the synthesis of microbiocidal heterobicyclic derivatives | |
| ZA202003528B (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| EP3596060C0 (en) | New bicyclic compounds as atx inhibitors | |
| IL282659A (en) | Heterocyclic compounds as bet inhibitors | |
| IL289617A (en) | Heterocyclic compounds | |
| IL289595A (en) | Heterocyclic compounds | |
| GB201819126D0 (en) | Inhibitor compounds | |
| IL289023A (en) | Bicyclic heterocyclic compounds as inhibitors ofbcdin3d activity | |
| ZA202103106B (en) | Heterocyclic compounds for the treatment of epilepsy | |
| GB201814067D0 (en) | Compounds for the inhibition of cyclophilins | |
| PT3710446T (en) | Compounds useful for inhibiting cdk7 | |
| GB201819136D0 (en) | Inhibitor compounds | |
| GB201806130D0 (en) | Inhibitor compounds | |
| GB201806131D0 (en) | Inhibitor compounds |